Last Friday the FDA announced that Xanodyne Pharmaceuticals had agreed to withdraw propoxyphene – better known by the brand names Darvon and Darvocet – from the U.S. market due to new data showing that the drug can cause serious toxicity to the heart, even when used at therapeutic doses.
The FDA concluded that the safety risks of propoxyphene outweighed its benefits for pain relief at recommended doses. They also requested that the generic manufacturers of propoxyphene-containing drugs...

